Elizabeth Orr
Elizabeth Orr is managing editor of US regulatory and policy for Medtech Insight, which she joined in 2015 as a reporter focused on legal issues. She remains fascinated by the ever-changing master class on technology, government regulations, advances in health care and more that is covering the device industry. Elizabeth’s past employers include FDANews; DecisionHealth (formerly UCG); the Society of Interventional Radiology; and the Washington Examiner. A graduate of the College of Journalism at the University of Maryland College Park, she lives in Arlington, Va., with her husband and children.
Latest From Elizabeth Orr
Industry And Investors Ponder Legacy Of Theranos Scandal
What lessons can be learned from the conviction of Theranos founder Elizabeth Holmes, found guilty on four counts of investor fraud in a US court on 4 January?
Attorneys Mull Takeaways From Conviction Of Theranos Founder Holmes
Elizabeth Holmes has been convicted on four counts of investor fraud. Two attorneys who followed the case spoke to Medtech Insight about what happened – and what it could mean for industry as a whole.
Warning Letter Close-Outs – December 2021
The US FDA released only one device-related close-out letter last month.
FDA Finalizes Guidance On Multi-Patient Arthroscopy Tubing
The document from the US agency details features and testing protocols expected to diminish the risk of “backflow,” in which contaminated fluid is transferred from one patient to another.
US FDA Device Center Hopes For ‘Normal Operations’ In 2022
Some device center functions should be back to user-fee timelines next year, but delays will persist in the divisions hardest hit by COVID-19, a blog post by top agency officials says.
Device Week, 17 December 2021 – Califf’s US Senate Hearing; Medtronic And BrainsGate’s Woes; US FDA Defines Counterfeit Devices
On this week’s podcast: Robert Califf goes through his first round nomination hearing in the Senate again, Medtronic and BrainsGate hits their own snags, and the US FDA defines counterfeit products under its new authorities.